Source comparison
Ipamorelin Results After 1 Month: Peptide Secretagogue Comparison
Ipamorelin Selective ghrelin receptor agonist (GHS-R1a). No cortisol/prolactin stimulation 15–30% above baseline Improved sleep quality, faster recovery, subtle fat reduction (3–7%), minimal physique change Minimal. Occasional transient hunger, rare injection
This comparison does not assign a generated winner or score.
- Ipamorelin
- Selective ghrelin receptor agonist (GHS-R1a). No cortisol/prolactin stimulation
- 15–30% above baseline
- Improved sleep quality, faster recovery, subtle fat reduction (3–7%), minimal physique change
- Minimal. Occasional transient hunger, rare injection site irritation
- Best choice for clean, sustainable GH elevation without HPTA suppression or secondary hormone disruption
- CJC-1295 (DAC)
- GHRH analog with extended half-life (6–8 days)
- 25–40% above baseline
- Similar to ipamorelin but with more pronounced water retention and fullness
- Moderate. Subcutaneous water retention common, potential for desensitization with continuous elevation
- Stronger IGF-1 response but less physiologically pulsatile. Often stacked with ipamorelin rather than used solo
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic (non-peptide)
- 30–50% above baseline
- Increased appetite, improved sleep, visible water retention
- High. Significant hunger increase, lethargy in some users, fasting glucose elevation risk
- Most convenient (oral), but appetite stimulation and metabolic side effects limit usability in fat-loss protocols
- GHRP-2
- Non-selective ghrelin receptor agonist
- 20–35% above baseline
- Improved recovery and sleep, but with cortisol and prolactin co-release
- Moderate to high. Cortisol elevation (10–20% above baseline), potential prolactin-related gynecomastia risk
- Older-generation secretagogue. Ipamorelin largely replaced it due to cleaner receptor selectivity